Gilead rescues biopharma’s takeout scene
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
Gilead’s cancer ambitions stretch to $21bn
As Immunomedics and Seattle both get backing from the big boys, antibody-drug conjugates finally come of age.
Esmo 2020 preview – late-breaking immunotherapy
The upcoming virtual Esmo congress gives top billing to big pharma immunotherapies.
Another Astra-Daiichi tie-up puts Trop2 in focus
The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
